---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-021144"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2024-05-23T23:59:59+00:00"
generated_at: "2026-06-01T09:12:40.915911+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Oncocyte enters employment agreement with CSO; base salary $351,525

## Summary
- Employment agreement with Chief Science Officer Ekkehard Schütz effective May 20, 2024; four-year term.
- Base salary of $351,525.20; eligible for annual cash bonus of 50% of base salary.
- Severance upon termination without cause or good reason includes 12 months base salary, pro-rata bonus, health coverage, and accelerated equity vesting.
- Agreement replaces prior Managing Director Service Agreement with Chronix Biomedical GmbH.

## SEC filing metadata
- accession: 0001493152-24-021144
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2024-05-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315224021144/0001493152-24-021144-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315224021144/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-021144
- JSON: https://secwatch.observer/filing/0001493152-24-021144.json
- Plain text: https://secwatch.observer/filing/0001493152-24-021144.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.